Literature DB >> 19787837

Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review.

Pei-Min Hsieh1, Kao-Chen Hung, Yaw-Sen Chen.   

Abstract

Tumor lysis syndrome (TLS) is a potentially lethal complication in cancer therapy. It may occur in highly sensitive tumors, especially in childhood cancer and leukemia, whereas, it is rare in the treatment of solid tumors in adults. TLS results from a sudden and rapid release of nuclear and cytoplasmic degradation products of malignant cells. The release of these can lead to severe alterations in the metabolic profile. Here, we present two cases of large hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) that resulted in TLS. Although TLS rarely happens in the treatment of adult hepatic tumor, only a few cases have been reported. We should keep in mind that all patients with HCC, particularly those with large and rapidly growing tumors, must be closely watched for evidence of TLS after TACE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787837      PMCID: PMC2754522          DOI: 10.3748/wjg.15.4726

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

Review 1.  Management of acute tumor lysis syndrome.

Authors:  S Sallan
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

2.  Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer.

Authors:  A Y Rostom; G El-Hussainy; A Kandil; A Allam
Journal:  Ann Oncol       Date:  2000-10       Impact factor: 32.976

3.  Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma.

Authors:  Noriaki Sakamoto; Shuichi Monzawa; Hidenobu Nagano; Hogara Nishizaki; Yasuaki Arai; Kazuro Sugimura
Journal:  Cardiovasc Intervent Radiol       Date:  2007 May-Jun       Impact factor: 2.740

4.  Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma.

Authors:  L F Cohen; J E Balow; I T Magrath; D G Poplack; J L Ziegler
Journal:  Am J Med       Date:  1980-04       Impact factor: 4.965

Review 5.  Tumour lysis syndrome: new therapeutic strategies and classification.

Authors:  Mitchell S Cairo; Michael Bishop
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

Review 6.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

Review 7.  Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor.

Authors:  Hassanali H Sewani; Jeffrey T Rabatin
Journal:  Mayo Clin Proc       Date:  2002-07       Impact factor: 7.616

8.  Acute renal failure from spontaneous acute tumor lysis syndrome: a case report and review.

Authors:  Samer Alkhuja; Harry Ulrich
Journal:  Ren Fail       Date:  2002-03       Impact factor: 2.606

9.  Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study.

Authors:  Teh-Ia Huo; Jaw-Ching Wu; Pui-Ching Lee; Full-Young Chang; Shou-Dong Lee
Journal:  Liver Int       Date:  2004-06       Impact factor: 5.828

Review 10.  Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.

Authors:  Michael B Davidson; Snehal Thakkar; John K Hix; Naveen D Bhandarkar; Alan Wong; Martin J Schreiber
Journal:  Am J Med       Date:  2004-04-15       Impact factor: 4.965

View more
  19 in total

Review 1.  Spontaneous tumour lysis syndrome.

Authors:  Natasha Kekre; Bojana Djordjevic; Claire Touchie
Journal:  CMAJ       Date:  2012-04-10       Impact factor: 8.262

2.  Tumour Lysis Syndrome: a Rare Complication of Trans-Arterial Chemo-Embolisation with Doxorubicin Beads for Hepatocellular Carcinoma.

Authors:  Diana Katiman; Jeeta Manikam; Khean-Lee Goh; Basri Johan Abdullah; Sanjiv Mahadeva
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 3.  Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures.

Authors:  Ali Faramarzalian; Keith B Armitage; Baljendra Kapoor; Sanjeeva P Kalva
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

Review 4.  A focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologist.

Authors:  Marcia Friedman; Pritesh R Patel; Damiano Rondelli
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

Review 5.  Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature.

Authors:  Sean P Zivin; Youssef Elias; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

6.  Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study.

Authors:  Tongchun Xue; Fan Le; Rongxin Chen; Xiaoying Xie; Lan Zhang; Ningling Ge; Yi Chen; Yanhong Wang; Boheng Zhang; Shenglong Ye; Zhenggang Ren
Journal:  Med Oncol       Date:  2015-02-15       Impact factor: 3.064

7.  A case of gouty arthritis following percutaneous radiofrequency ablation for hepatocellular carcinoma.

Authors:  Dae Hee Choi; Hyo-Suk Lee
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

8.  Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients.

Authors:  Zhong Ye; Juan P Palazzo; Liz Lin; Yinzhi Lai; Fran Guiles; Ronald E Myers; Jin Han; Jinliang Xing; Hushan Yang
Journal:  J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 4.029

9.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

Review 10.  Therapeutics for paediatric oncological emergencies.

Authors:  Karen Ka Yan Leung; Kam Lun Hon; Wun Fung Hui; Alexander Kc Leung; Chi Kong Li
Journal:  Drugs Context       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.